Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to
assess the effects and safety of Lanadelumab in patients with FXII-associated cold
autoinflammatory syndrome (FACAS).